Track Abbott Laboratories — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Abbott Laboratories ABT.SW · Stock Open Abbott Laboratories in new tab

72.50 CHF
P/E
29.59
EPS
2.45
Yield
2.40%
Safety Score
72
P/B
2.93
ROE
10.58
Beta
0.59
Loading chart...
Key Metrics
Earnings dateOct. 14, 2026
P/E29.59
EPS2.45
Book Value24.72
Price to Book2.93
Debt/Equity63.21
% Insiders0.492%
Growth
Revenue Growth0.13%
Earnings Growth-0.48%
Dividend
Dividend Yield2.40%
Annual dividends2.48 CHF
Ex-Div. DateOct. 15, 2026
Payout78.54%
5y avg Yield1.91%

DCF Valuation

Tweak assumptions to recompute fair value for Abbott Laboratories (ABT.SW)
Currency: CHF
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Abbott Laboratories Logo Abbott Laboratories Analysis (ABT.SW)

United States Health Care Official Website Stock

Is Abbott Laboratories a good investment? Abbott Laboratories (ABT.SW) is currently trading at 72.50 CHF.

In terms of valuation, the stock trades at a P/E ratio of 29.59. This valuation is generally in line with the broader market.

Earnings Schedule: Abbott Laboratories is expected to release its next earnings report on Oct. 14, 2026.

For income investors, Abbott Laboratories pays a dividend yield of 2.40%. With a payout ratio of 79%, the dividend appears to be under pressure.

Investor FAQ

Does Abbott Laboratories pay a dividend?

Yes, it pays an annual dividend of 2.48 CHF (2.40% yield).

What asset class is Abbott Laboratories?

Abbott Laboratories is classified as a Stock. You can compare it against 12 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Oct. 14, 2026. The company currently has a trailing EPS of 2.45.

Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Exchange Ticker
SGO (Chile) ABTCL.SN
SGO (Chile) ABT.SN
MEX (Mexico) ABT.MX
FRA (Germany) ABL.F
VIE (Austria) ABT.VI
BUE (Argentina) ABT.BA
MIL (Italy) ABT.MI
SAO (Brazil) ABTT34.SA
STU (Germany) ABL.SG
GER (Germany) ABL.DE
NYQ (United States) ABT
EBS (Ireland) ABT.SW
Trades
Dividend Yield
2.40%
5y avg 1.91%
Annual Dividends
2.48CHF
Next Ex. Div Date
Oct. 15, 2026
Payout Ratio
78.54%
Dividend History paid per year (CHF)
Historical Dividends
Year Total Dividends
▸2027
1.64 CHF
Aug. 16, 2027 (estimated) 0.5618
May 17, 2027 (estimated) 0.5428
Feb. 15, 2027 (estimated) 0.5307
▸2026
2.01 CHF
Nov. 16, 2026 0.5197
Aug. 17, 2026 0.5092
May 15, 2026 0.4934
Feb. 13, 2026 0.4921
▸2025
1.96 CHF
Nov. 17, 2025 0.4609
Aug. 15, 2025 0.4737
May 15, 2025 0.4866
Feb. 14, 2025 0.5387
▸2024
1.94 CHF
Nov. 15, 2024 0.4749
Aug. 15, 2024 0.4927
May 15, 2024 0.5031
Feb. 15, 2024 0.4687
▸2023
1.83 CHF
Nov. 15, 2023 0.4635
Aug. 15, 2023 0.4383
May 15, 2023 0.4540
Feb. 15, 2023 0.4732
▸2022
1.80 CHF
Nov. 15, 2022 0.4707
Aug. 15, 2022 0.4626
May 16, 2022 0.4395
Feb. 15, 2022 0.4283
▸2021
1.64 CHF
Nov. 15, 2021 0.4159
Aug. 16, 2021 0.4122
May 17, 2021 0.4154
Feb. 16, 2021 0.4000
▸2020
1.36 CHF
Nov. 16, 2020 0.3284
Aug. 15, 2020 0.3380
May 15, 2020 0.3459
Feb. 14, 2020 0.3486
▸2019
1.27 CHF
Nov. 15, 2019 0.3195
Aug. 15, 2019 0.3153
May 15, 2019 0.3204
Feb. 15, 2019 0.3139
▸2018
1.10 CHF
Nov. 15, 2018 0.2778
Aug. 15, 2018 0.2800
May 15, 2018 0.2695
Feb. 15, 2018 0.2730
▸2017
1.05 CHF
Nov. 15, 2017 0.2587
Aug. 15, 2017 0.2555
May 15, 2017 0.2666
Feb. 15, 2017 0.2713
Upcoming Dividends
Name Payment Date Status Amount
Abbott Laboratories Nov 16, 2026 Upcoming 0.51972 CHF
Abbott Laboratories Aug 17, 2026 0.50918 CHF
Abbott Laboratories May 15, 2026 0.4934 CHF
Abbott Laboratories Feb 13, 2026 0.49212 CHF
Abbott Laboratories Nov 17, 2025 0.46087 CHF
Stock Splits
Split Date Split Ratio to 1
Jan. 3, 2013 2:1
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion